Carpal Tunnel Syndrome | NYU Langone Health
NYU Langone physicians and therapists work together to create a customized treatment plan for people with carpal tunnel syndrome.
Cataract | NYU Langone Health
NYU Langone doctors use the latest technology to remove a cataract and restore eyesight safely and successfully.
Catheter Ablation for Atrial Fibrillation & Atrial Flutter | NYU Langone Health
NYU Langone heart rhythm specialists perform catheter ablation to manage and even stop the symptoms of atrial fibrillation and atrial flutter.
Catheter Ablation for Supraventricular Arrhythmias | NYU Langone Health
NYU Langone heart rhythm specialists may perform catheter ablation to manage a supraventricular arrhythmia.
Catheter-Based Treatments for Adult Congenital Heart Disease | NYU Langone Health
NYU Langone experts perform procedures, including cardiac catheterization and catheter ablation, to manage adult congenital heart disease.
CBYL719F12201: EPIK-P2 Phase II double-blind study w/ upfront 16-week randomized placebo-controlled period to assess efficacy safety & pharmacokinetics of alpelisib (BYL719) in pediatric & adult patients w/ PIK3CA-related overgrowth spectrum (PROS)
This study will be the first prospective study of alpelisib in participants with PROS. Local overgrowth or hemihypertrophy, mostly progressive, is the most frequently observed manifestation of the disease, often causing functional and/or mobility impairment andreduction in health related quality of life. The first experience with alpelisib in overgrowth related to mutation in PIK3CA gene provides the direct evidence of clinical improvement in participants supporting PIK3CA inhibition as a promising therapeutic strategy in participants with PROS. PROS is a serious condition with no approved pharmacological treatment targeting the underlying cause of the disease. Current therapy includes debulking surgery, amputation, and/or endovascular occlusive procedures and mainly addresses symptoms and complications of the disease. There is a high unmet medical need for an effective systemic treatment.The purpose of this study is to assess the efficacy, safety/tolerability and evaluate pharmacokinetics (PK) of alpelisib in participants of different ages with confirmed diagnosis of PROS. As the disease continues throughout the participant life and may be diagnosed at different time points (Keppler-Noreuil et al 2014), the study will enroll adult participants (Group 1; treated with film-coated tablets (FCT)), 6-17 years old pediatric participants (Group 2; treated with FCT), and two exploratory sets of 2-5 years old pediatric participants (Group 3 treated with granules and Group 4 treated with FCT).Group 3 will be enrolled after the completion of the primary analysis when the efficacy, safety and PK data will be available from the participants in Groups 1 and 2 in addition to the data from Group 4 as available, in order to select the recommended dose forparticipants in Group 3. Recruitment of participants in Group 3 will start only after submission and approval of a Substantial Global Protocol Amendment specific to this group. Group 4 will be enrolled before Group 3 and immediately after implementation of this Global Protocol Amendment 01.
CCI-Mobile: Signal Processing Advancements for Cochlear Implant Users in Naturalistic Environments
The proposed multi-center research effort seeks to explore the novel research directions made possible by a flexible, powerful, portable speech processor (CCi-MOBILE) for cochlear implants based on commercially available smartphones/tablets. This research platform will be significantly more flexible and computationally powerful than clinical devices, and will enable implementation and long-term evaluation of advanced signal processing algorithms in naturalistic, diverse acoustic environments. It will be combined with take-home assessments of novel front-end speech enhancement/processing strategies that are inspired by human speech physiology
Celiac Disease & Gluten Sensitivity | NYU Langone Health
At NYU Langone, gastroenterologists specialize in the diagnosis and management of celiac disease and gluten sensitivity.
Celiac Disease in Children | NYU Langone Health
Specialists at NYU Langone work together to help children and their families manage celiac disease effectively.
Cellular Viscosity as a Marker for Alzheimer s Disease Pathology: A Combined Multiparametric MR Spectroscopy and PET Study
This project proposes the use of Magnetic Resonance Spectroscopic Fingerprinting (MRSF) to quantify changes in intracellular viscosity separately within neurons and astrocytes and assess AD pathophysiology. We will work with the NYU AD Research Center to include our MRSF sequence within their routine tau-PET/MRI protocol, allowing for serial follow-up of a cohort of 100 cognitively normal individuals and patients with mild cognitive impairment. Both sets of subjects will undergo yearly neurocognitive assessments, plasma Aß and plasma tau evaluations; and biennial Aß-PET, tau-PET, and MRI+MRSF scans. The expected outcome of this work is a set of novel markers for neuronal and astrocytic intracellular viscosity which will potentially become biomarkers for early prediction of neurodegeneration and cognitive decline in AD, addressing gaps in the current imaging armamentarium of the AT(N) network.